Stockscreener 앱 받기
1.06
4.50%
-0.05
시간 외 거래:
1.06
전일 마감가:
$1.11
열려 있는:
$1.07
하루 거래량:
815.53K
Relative Volume:
0.44
시가총액:
$18.21M
수익:
-
순이익/손실:
$-11.90M
주가수익비율:
-0.00515
EPS:
-206.0125
순현금흐름:
$-12.75M
1주 성능:
-0.93%
1개월 성능:
+33.99%
6개월 성능:
-25.87%
1년 성능:
+6.00%
1일 변동 폭
$1.0235
$1.09
1주일 범위
$1.0235
$1.23
52주 변동 폭
$0.1131
$3.95
Allarity Therapeutics Inc Stock (ALLR) Company Profile
명칭
Allarity Therapeutics Inc
전화
401-426-4664
주소
24 SCHOOL ST., 2ND FLOOR, BOSTON
ALLR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.06 | 18.21M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
ALLR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Allarity Therapeutics, Inc. - ACCESS Newswire
You might want to take a look at Allarity Therapeutics Inc (ALLR) now - Sete News
Was anything positive for Allarity Therapeutics Inc (ALLR) stock last session? - uspostnews.com
The Psychology of Allarity Therapeutics Inc Inc. (ALLR) Price Performance: Understanding Market Sentiment - investchronicle.com
Upward Trajectory: Allarity Therapeutics Inc (ALLR) Posts a Slidee, Closing at 1.07 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Allarity unveils new multiple myeloma treatment predictor - Investing.com
Allarity unveils new multiple myeloma treatment predictor By Investing.com - Investing.com South Africa
Healthy Upside Potential: Allarity Therapeutics Inc (ALLR) - Sete News
Allarity Therapeutics Presents Novel Drug Response - GlobeNewswire
Novel AI Predictor Identifies Multiple Myeloma Patients for Targeted Treatment | ALLR Stock News - Stock Titan
Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX
How to interpret Allarity Therapeutics Inc (ALLR)’s stock chart patterns - uspostnews.com
Allarity Therapeutics Inc (ALLR) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Allarity Therapeutics Restructures Board of Directors - TipRanks
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire
Allarity Therapeutics stock hits 52-week low at $0.67 - Investing.com
Allarity Therapeutics stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada
There is no way Allarity Therapeutics Inc (ALLR) can keep these numbers up - Sete News
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - Stocksregister
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Allarity Therapeutics, Inc. SEC 10-K Report - TradingView
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire
Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 - Stock Titan
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter
Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World
Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia
Allarity Therapeutics probes potential stock manipulation - Investing.com
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan
Investigation announced for Long-Term Investors in shares - openPR.com
ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq
Allarity Therapeutics Inc (ALLR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):